Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) and approved for treatment of
various malignancies. Hereditary genetic variants may affect a drug's pharmacokinetics or …

Purpose: Nucleotide excision repair (NER) modulates platinum-based chemotherapeutic
efficacy by removing drug-produced DNA damage. To summarize published data on the …

Oxaliplatin-based chemotherapy is the standard of care in patients with high-risk stage II and
stage III colorectal cancer as well as in patients with advanced disease. Unfortunately, a …

Objectives Many primary studies have considered the association of polymorphisms of folate
metabolism and response to 5-fluorouracil (5-FU) and capecitabine in patients with …

Background: While single nucleotide polymorphisms (SNP) in genes involved in DNA repair
or drug metabolism have been shown to influence survival of metastatic colon cancer …

Objectives To determine the correlation between expression of three DNA repair genes and
early failure/clinical outcome of stage III colorectal cancer (CRC) patients administrated with …

Purpose The relationship between the excision repair cross-complementing 1 (ERCC1)
rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric …

Background: The study aims to evaluate the contribution of excision repair cross-
complementing group 1 (ERCC1), which plays an important role in genome integrity …

Inter-ethnic differences in drug handling and frequencies of pharmacogenetic variants are
increasingly being characterized. In this study, we systematically assessed the feasibility of …

Background: Although the predictive value of the excision repair cross-complementing
group 1 (ERCC1) C118T polymorphism in clinical outcomes of patients with colorectal …